These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 27626100)

  • 1. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
    Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T
    ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.
    Barnaby R; Koeppen K; Nymon A; Hampton TH; Berwin B; Ashare A; Stanton BA
    Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L432-L438. PubMed ID: 29146575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
    Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
    Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Fresh Shine onCystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles.
    Jasim R; Schneider EK; Han M; Azad MAK; Hussein M; Nowell C; Baker MA; Wang J; Li J; Velkov T
    J Biomed Nanotechnol; 2017 Apr; 13(4):447-57. PubMed ID: 29384621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Infectives Restore ORKAMBI
    Laselva O; Stone TA; Bear CE; Deber CM
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32092967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
    Connett GJ
    Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider EK; Reyes-Ortega F; Li J; Velkov T
    Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Enhances Ciprofloxacin Activity Against Pseudomonas aeruginosa.
    Cho DY; Lim DJ; Mackey C; Skinner D; Zhang S; McCormick J; Woodworth BA
    Am J Rhinol Allergy; 2019 Mar; 33(2):129-136. PubMed ID: 30585080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor.
    Schneider EK
    Drug Metab Lett; 2018; 12(1):71-74. PubMed ID: 29595119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.
    Singh SB; McLearn-Montz AJ; Milavetz F; Gates LK; Fox C; Murry LT; Sabus A; Porterfield HS; Fischer AJ
    Pediatr Pulmonol; 2019 Aug; 54(8):1200-1208. PubMed ID: 31012285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis.
    Hammond JA; Connett GJ
    Paediatr Respir Rev; 2018 Jun; 27():16-17. PubMed ID: 29914743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor.
    Cho DY; Lim DJ; Mackey C; Weeks CG; Peña Garcia JA; Skinner D; Grayson JW; Hill HS; Alexander DK; Zhang S; Woodworth BA
    Int Forum Allergy Rhinol; 2018 May; 8(5):577-583. PubMed ID: 29412515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival.
    Hazlett HF; Hampton TH; Aridgides DS; Armstrong DA; Dessaint JA; Mellinger DL; Nymon AB; Ashare A
    Sci Rep; 2020 Jul; 10(1):10935. PubMed ID: 32616918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis.
    Kopp BT; McCulloch S; Shrestha CL; Zhang S; Sarzynski L; Woodley FW; Hayes D
    Pediatr Pulmonol; 2018 May; 53(5):583-591. PubMed ID: 29461009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.
    Schneider EK; Reyes-Ortega F; Wilson JW; Kotsimbos T; Keating D; Li J; Velkov T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1038():57-62. PubMed ID: 27792891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts.
    Adam D; Bilodeau C; Sognigbé L; Maillé É; Ruffin M; Brochiero E
    J Cyst Fibros; 2018 Nov; 17(6):705-714. PubMed ID: 29661510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.